Valneva reported results from its phase 3 trial, Cov-Compare designed to assess immunogenicity rates between VLA200 and active comparator vaccine, AstraZeneca’s AZD1222 (ChAdOx1-S). VLA2001 successfully met both co-primary…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.